96 related articles for article (PubMed ID: 15125945)
1. PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues.
Abbott BM; Thompson PE
Bioorg Med Chem Lett; 2004 Jun; 14(11):2847-51. PubMed ID: 15125945
[TBL] [Abstract][Full Text] [Related]
2. Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity.
Abbott BM; Thompson PE
Bioorg Med Chem Lett; 2006 Feb; 16(4):969-73. PubMed ID: 16290931
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
5. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide 3-kinase is involved in Xenopus and Labrus melanophore aggregation.
Andersson TP; Sköld HN; Svensson SP
Cell Signal; 2003 Dec; 15(12):1119-27. PubMed ID: 14575867
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
8. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
Castro A; Jerez MJ; Gil C; Martinez A
Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of lipolysis in adipocytes from fed rats, but not from starved rats, by inhibition of rolipram-sensitive phosphodiesterase 4.
Nakamura J; Okamura N; Kawakami Y
Arch Biochem Biophys; 2004 May; 425(1):106-14. PubMed ID: 15081899
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
Netherton SJ; Maurice DH
Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
12. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors.
Favot L; Keravis T; Holl V; Le Bec A; Lugnier C
Thromb Haemost; 2003 Aug; 90(2):334-43. PubMed ID: 12888882
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors.
Jiang W; Alford VC; Qiu Y; Bhattacharjee S; John TM; Haynes-Johnson D; Kraft PJ; Lundeen SG; Sui Z
Bioorg Med Chem; 2004 Mar; 12(6):1505-15. PubMed ID: 15018924
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site.
Roma G; Di Braccio M; Grossi G; Piras D; Leoncini G; Bruzzese D; Signorello MG; Fossa P; Mosti L
J Med Chem; 2007 Jun; 50(12):2886-95. PubMed ID: 17500510
[TBL] [Abstract][Full Text] [Related]
15. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of platelet PDE2 by an affinity label: 8-[(4-bromo-2, 3-dioxobutyl)thio]cAMP.
Mseeh F; Colman RF; Colman RW
Thromb Res; 2000 Jun; 98(5):395-401. PubMed ID: 10828479
[TBL] [Abstract][Full Text] [Related]
17. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.
Uddin S; Hussain AR; Al-Hussein KA; Manogaran PS; Wickrema A; Gutierrez MI; Bhatia KG
Clin Cancer Res; 2005 Apr; 11(8):3102-8. PubMed ID: 15837766
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
20. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
Benjamin CW; Lin AH; Morris J; Wishka DG; Gorman RR
J Pharmacol Exp Ther; 1993 Apr; 265(1):457-62. PubMed ID: 7682615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
